

## **BCFU MRF Forms – Summary of Version Changes**

### Version 2:

- Added Weight prior to surgery and treatment
- Added Multifocal tumor
- Separated Tumor Size (single longest dimension in cm) into separate questions for Invasive tumor size and In situ tumor size
- Separated Tumor Histology – Ductal into separate questions for Invasive ductal only and In Situ ductal only
  - Added Micropapillary option for tumor histologies
  - Added Necrosis option for tumor histologies
- Added Necrosis option for Tumor histology – lobular
- Separated Grade into Invasive grade and In situ grade
- Added Nucleic acid amplification (eg RT-PCR) and Other, specify options for Estrogen Receptor Assay (ERA) type
- Added Nucleic acid amplification (eg RT-PCR) and Other, specify options for Progesterone Receptor Assay (PRA) Type
- Added Other, specify option for HER-2/NEU assay type
- Added HER-2/NEU value (FISH)
- Added surgical treatment dates/type for second and third post-diagnosis surgeries
- Added Closest final margin (Positive/Negative)
- Added If metastatic, which distal sites were affected
- Expanded list of chemotherapy regimens for Adjuvant chemotherapy
- Added Internal radiation technique used
- Added Treatment toxicity side effects present
- Added If yes, treatment toxicity side effects
- Removed Other Genetic testing
- Added assay types to table for Molecular Profiling Proliferation assay: Ki-67, E-cadherin, OncotypeDX, p53, p63

### Version 3:

- No significant content changes

### Version 4:

- No significant content changes

### Version 5:

- Added multicentric option for Quadrant Location
- Added LCIS present
- Added equivocal option for Results of HER-2/NEU value (FISH)
- Added Biopsy (entire tumor removed) option for Type of Surgery
- Added Tumor found in last surgery
- Added Node staging (per pathology report) for Lymph node involvement

- Added Results of metastatic work up post diagnosis
- Added If metastatic post diagnosis, which distal sites were affected
- Added # Cycles for Biological Therapy treatment
- Changed Dosage to Prescribed Dosing Interval for Biological Therapy treatment
- Added Pre-DX checkbox for Hormonal Treatment
- Removed Site unknown option for Radiation Treatment
- Changed Cumulative Dose (cGy) to Dose (cGy) for Radiation Treatment
- Added IMRT used
- Added options for treatment toxicity side effects: Osteodynia, Arthralgia, and Leukopenia
- Added If done, how many sites for BRCA1 and BRCA2 genetic testing

Version 6:

- Added space for both Accession # and Pathology # under Pathology accession number(s)
- Diploid/Euploid/Normal DNA Index value changed from 1.0 to 1.1
- Aneuploid/Abnormal for DNA ploidy cutoff changed from DNA Index>1.0 to DNA Index>1.1
- Hypodiploid added for DNA ploidy
- Date of metastatic workup post diagnosis added
- Added Other Chemotherapy regimen (non-cytotoxic)
- Separated external and internal radiation therapies

Version 7:

- Added Diagnostic histology (ICDO-3/behavior)
- Added general Genetic testing performed question
- Added Other germline testing done (non-BRCA)
- Added If yes, specify other type of germline testing

Version 8:

- Added options for Quadrant location: Extension to chest wall, Ulceration, Ipsilateral satellite nodules, Edema of the skin
- Added Accession Line # for each post-diagnosis surgery

Version 9:

- Addition of completion status (comp./disc.) for questions 42, 44, 44x, 46, 48, 50, 51b